AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 65.2 |
Market Cap | 3.94B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -4.55 |
PE Ratio (ttm) | -35.38 |
Forward PE | n/a |
Analyst | Buy |
Ask | 257.72 |
Volume | 92,732 |
Avg. Volume (20D) | 219,226 |
Open | 158.94 |
Previous Close | 158.15 |
Day's Range | 157.58 - 161.66 |
52-Week Range | 86.80 - 196.26 |
Beta | undefined |
About ICUI
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for h...
Analyst Forecast
According to 4 analyst ratings, the average rating for ICUI stock is "Buy." The 12-month stock price forecast is $200, which is an increase of 24.22% from the latest price.
Next Earnings Release
Analysts project revenue of $599.10M, reflecting a 1.91% YoY growth and earnings per share of 1.48, making a -5.73% decrease YoY.